Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Wipro Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Wipro Limited trades at $1.9 (market cap $18.38B). The key difference: Wipro Limited is far larger — about 22.2× Amphastar Pharmaceuticals Inc's market cap, and Wipro Limited pays a 10.25% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WIT | |
|---|---|---|
Market Cap | $826.08M | $18.38B |
Sector | Health | Technology |
52-Week High | $30.81 | $3.06 |
52-Week Low | $16.87 | $1.82 |
Enterprise Value | $1.22B | $14.77B |
Dividend Yield | — | 10.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
WIT trades at $1.87, up 1.08% today, but faces bearish technical signals with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. Fundamentals show solid profitability with a 14.25% net margin and 15.4% ROE, while valuation metrics like a P/E of 14.05 appear reasonable. Recent news highlights AI partnerships with ServiceNow and Anthropic, though weak Q2 2026 guidance has pressured sentiment.
The outlook is cautious with mixed analyst ratings (19% buy, 48% hold, 33% sell) and near-term revenue headwinds. Investment opportunities lie in AI-driven growth initiatives, but risks include execution challenges and competitive pressures in the IT services sector. Cash flow remains strong at $25.02B net for 2025, supporting financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
